129 related articles for article (PubMed ID: 18776074)
41. Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.
Shand B; Scott R; Connolly S; Clarke R; Baker J; Elder P; Frampton C; Yeo J
Diabetes Obes Metab; 2007 Jul; 9(4):540-7. PubMed ID: 17587396
[TBL] [Abstract][Full Text] [Related]
42. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
43. A longitudinal follow-up study of a type 2 diabetes "lost to follow-up" cohort - positive effect on glycaemic control after changes in medication.
Kauppila T; Laine MK; Honkasalo M; Raina M; Eriksson JG
Int J Circumpolar Health; 2020 Jan; 79(1):1773127. PubMed ID: 32498629
[TBL] [Abstract][Full Text] [Related]
44. Impact of a chronic care model based on patient empowerment on the management of Type 2 diabetes: effects of the SINERGIA programme.
Musacchio N; Lovagnini Scher A; Giancaterini A; Pessina L; Salis G; Schivalocchi F; Nicolucci A; Pellegrini F; Rossi MC
Diabet Med; 2011 Jun; 28(6):724-30. PubMed ID: 21294769
[TBL] [Abstract][Full Text] [Related]
45. Telemedicine and diabetes: achievements and prospects.
Franc S; Daoudi A; Mounier S; Boucherie B; Dardari D; Laroye H; Neraud B; Requeda E; Canipel L; Charpentier G
Diabetes Metab; 2011 Dec; 37(6):463-76. PubMed ID: 21889388
[TBL] [Abstract][Full Text] [Related]
46. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial.
Webb DR; Khunti K; Gray LJ; Srinivasan BT; Farooqi A; Wareham N; Griffin SC; Davies MJ;
Diabet Med; 2012 Apr; 29(4):531-40. PubMed ID: 21913966
[TBL] [Abstract][Full Text] [Related]
47. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
Cook MN; Girman CJ; Stein PP; Alexander CM
Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
[TBL] [Abstract][Full Text] [Related]
48. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
49. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin.
Blak BT; Smith HT; Hards M; Curtis BH; Ivanyi T
Diabet Med; 2012 Jul; 29(7):e13-20. PubMed ID: 22268988
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis.
Tricco AC; Ivers NM; Grimshaw JM; Moher D; Turner L; Galipeau J; Halperin I; Vachon B; Ramsay T; Manns B; Tonelli M; Shojania K
Lancet; 2012 Jun; 379(9833):2252-61. PubMed ID: 22683130
[TBL] [Abstract][Full Text] [Related]
51. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
52. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
53. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
54. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
55. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
[TBL] [Abstract][Full Text] [Related]
56. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
[TBL] [Abstract][Full Text] [Related]
57. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
[TBL] [Abstract][Full Text] [Related]
58. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
[TBL] [Abstract][Full Text] [Related]
59. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
60. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
Xu T; Brandmaier S; Messias AC; Herder C; Draisma HH; Demirkan A; Yu Z; Ried JS; Haller T; Heier M; Campillos M; Fobo G; Stark R; Holzapfel C; Adam J; Chi S; Rotter M; Panni T; Quante AS; He Y; Prehn C; Roemisch-Margl W; Kastenmüller G; Willemsen G; Pool R; Kasa K; van Dijk KW; Hankemeier T; Meisinger C; Thorand B; Ruepp A; Hrabé de Angelis M; Li Y; Wichmann HE; Stratmann B; Strauch K; Metspalu A; Gieger C; Suhre K; Adamski J; Illig T; Rathmann W; Roden M; Peters A; van Duijn CM; Boomsma DI; Meitinger T; Wang-Sattler R
Diabetes Care; 2015 Oct; 38(10):1858-67. PubMed ID: 26251408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
